In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Top Financing Of 2016: Cast Your Vote!

Executive Summary

It's time once again for In Vivo's Deal of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners. (It's free.)

In Vivo's Top Financing Of 2016 –The Nominees Are:

Another Big Round For Moderna: The $474 million equity financing that the mRNA drug developer raised in September will cover R&D, manufacturing and pipeline expansion costs until it has proof-of-concept data in hand and can go public. [See Deal]

Grail Spins Out Of Illumina: In January, liquid biopsy play Grail Bio raised a $100 million-plus Series A round from top-flight investors, including majority owner Illumina. In December, Grail announced it's on the hunt for another $1.7 billion to fund a clinical trial in half a million people. [See Deal]

Corporate Venture Bolsters Akili: Merck Ventures and Amgen Ventures participated in Akili Interactive Labs' $42 million multi-tranche Series B round in 2016. The proceeds will fuel development of Akili's clinically-validated video game for assessing and treating cognitive disorders. [See Deal]

Samsung BioLogics' $2 Billion IPO: The November IPO, the third largest in South Korea's history, is a big validation for biologics development in that country and also shows the importance of diversification for parent Samsung. [See Deal]

DalCor Pharma Gets $100 Million For CETP Inhibitor: Hoping for better luck than its big pharma counterparts have had with CETP inhibitors, Dalcor closed a $100 million Series B round to fund Phase III trials of dalcetrapib (licensed from Roche, which terminated it for lack of efficacy) in a genetically distinct group of patients with acute coronary syndrome. [See Deal]

CLICK HERE To Cast Your Vote For The Most Significant Financing Of 2016

CLICK HERE to Cast Your Vote For The Most Significant Strategic Alliance Of 2016

Coming Up Next In IVDOTY16: Top M&A

Advertisement

Related Content

Top Alliance Of 2016: Cast Your Vote!
Huge Samsung BioLogics IPO Reflects Rosy Manufacturing Outlook
Moderna Prepares For mRNA Drug R&D Blitz With $474m In New Equity
Merck, Amgen Invest In Medical Video Game Developer Akili
DalCor To Develop Failed Roche CETP Inhibitor In Genetic Subgroup

Topics

Advertisement
UsernamePublicRestriction

Register

IV004990

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel